Research published in Journal of Affective Disorders (page 8)

The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review.

Journal of Affective Disorders December 1, 2022 Anastasia Levinta, Shakila Meshkat, Roger S McIntyre et al.

Ketamine has demonstrated rapid and significant antidepressant effects in patients with treatment resistant depression (TRD). Herein, we conducted a systematic review to determine ketamine's efficacy as a function of the stage of treatment resistance (e.g., number of failed treatments) among individuals with TRD. A systematic search of PubMed and Scopus from inception to August 2021 was...

DOI: 10.1016/j.jad.2022.08.050 Full text Arketamine Spravato Bdnf Bipolar +2

Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.

Journal of Affective Disorders December 1, 2022 Adrienne Lapidos, Daniela Lopez-Vives, Cortney E. Sera et al.

BACKGROUND Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression. A large data base is confirmatory and steadily expanding. Qualitative studies can inform best practices and suggest new research directions. As part of a clinical trial designed to identify biomarkers of ketamine response, a qualitative study was conducted to characterize experiences with: receiving...

DOI: 10.1016/j.jad.2022.11.090

Active mechanisms of ketamine-assisted psychotherapy: A systematic review.

Journal of Affective Disorders October 15, 2022 Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo et al.

Few studies have evaluated the efficacy of ketamine-assisted psychotherapy (KAP) in the treatment of treatment-resistant depression (TRD) and substance use disorders (SUD). A systematic review of clinical trials reporting on the efficacy of KAP and discussing mechanisms of action, identified on PubMed and PsycInfo. Five randomized-controlled trials reported on the efficacy of KAP treatment and...

DOI: 10.1016/j.jad.2022.07.030 Full text Ketamine Mood disorders Psychedelics Psychotherapy +2

The association of mindfulness and psychological well-being among individuals who have recovered from COVID-19 in Jianghan District, Wuhan, China: A cross-sectional study

Journal of Affective Disorders September 23, 2022 Zhenwei Dai, Hao Wang, Weijun Xiao et al. 15 citations

BACKGROUND: In the global pandemic of the coronavirus disease 2019 (COVID-19), depression and post-traumatic stress disorder (PTSD) have commonly occurred among COVID-19 patients, whose experiences of infection and subsequent treatment might develop negative consequences on their mental well-being even after recovery. Despite the general recognition of efficacy of mindfulness-based...

DOI: 10.1016/j.jad.2022.09.062

Mapping consent practices for outpatient psychiatric use of ketamine.

Journal of Affective Disorders September 1, 2022 David S. Mathai, Scott M Lee, Victoria Mora et al. 16 citations

Given increasing community-based and off-label use of ketamine for psychiatric indications, we examined current informed consent processes from a convenience sample of outpatient ketamine clinics to identify areas of congruence with current evidence and opportunities for growth. Using a rubric developed from existing practice guidelines, we conducted an exploratory analysis of informed consent...

DOI: 10.1016/j.jad.2022.06.036 Full text Depression Ketamine Consent Ethics +2

Effectiveness of mindfulness-based cognitive therapy against suicidal ideation in patients with depression: A systematic review and meta-analysis.

Journal of Affective Disorders September 1, 2022 Bing Zhang, Wenxian Fu, Yan Guo et al.

BACKGROUND Mindfulness-based cognitive therapy (MBCT) can effectively prevent relapse of major depression, but there is currently insufficient evidence for efficacy against suicidal ideation during depressive episodes. We thus conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing MBCT to treatment as usual (TAU) for suppression of suicidal ideation in...

DOI: 10.1016/j.jad.2022.09.091

Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.

Journal of Affective Disorders September 1, 2022 Melody J Y Kang, Gustavo Vazquez

BACKGROUND Major Depression is the leading cause of disability worldwide. A cohort of patients do not respond adequately to available antidepressants, leading to treatment-resistant depression (TRD). We evaluated the antidepressant efficacy of an acute intravenous ketamine treatment (0.5 mg/kg) for patients with unipolar TRD, and measured peripheral blood-based biomarkers associated with...

DOI: 10.1016/j.jad.2022.08.047

Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates.

Journal of Affective Disorders September 1, 2022 Madeline Brendle, Reid Robison, D. Malone

OBJECTIVE The aim of this study was to estimate the cost-effectiveness of esketamine nasal spray relative to intravenous ketamine for patients with treatment-resistant depression (TRD) in the US. METHODS We used a Markov model with a 1-month cycle length, and we estimated quality-adjusted life years (QALYs), costs (2020 USD), and incremental cost-effectiveness ratios (ICER) of esketamine...

DOI: 10.1016/j.jad.2022.09.083

At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.

Journal of Affective Disorders July 1, 2022 Thomas D Hull, Matteo Malgaroli, Adam Gazzaley et al. 59 citations

BACKGROUND At-home Ketamine-assisted therapy (KAT) with psychosocial support and remote monitoring through telehealth platforms addresses access barriers, including the COVID-19 pandemic. Large-scale evaluation of this approach is needed for questions regarding safety and effectiveness for depression and anxiety. METHODS In this prospective study, a large outpatient sample received KAT over...

DOI: 10.1016/j.jad.2022.07.004 Full text

Esketamine alleviates postoperative depression-like behavior through anti-inflammatory actions in mouse prefrontal cortex.

Journal of Affective Disorders April 1, 2022 Tian-Yuan Wang, H. Weng, Hong-Jin Zhou et al.

The rising incidence of Postoperative depression (POD) in recent years has placed a heavy burden on patients' physical and mental health. At this point in time, however, POD pathogenesis remains poorly understood and novel therapeutic strategies are being sought. The present study aimed to clarify esketamine's protective effects and possible mechanisms of action in POD. To this avail, we used...

DOI: 10.1016/j.jad.2022.03.072

Impact of online Mindfulness-Based Cognitive Therapy on suicidal ideation: A secondary analysis of a randomized trial of Mindful Mood Balance.

Journal of Affective Disorders March 15, 2022 Sona Dimidjian, Julia Kaufman, Natalie Coleman et al.

To address the elevated prevalence of depression, suicide, and suicidal ideation, patients require increased access to effective interventions. Mindfulness-Based Cognitive Therapy has a strong evidence base in relapse prophylaxis and can be delivered digitally through Mindful Mood Balance (MMB). This study was a secondary analysis of the impact of MMB paired with usual depression care (UDC)...

DOI: 10.1016/j.jad.2021.12.051 Full text Depression Mindfulness Suicidal ideation Suicide

Nightmares mediate the association between traumatic event exposure and suicidal ideation in frontline medical workers exposed to COVID-19

Journal of Affective Disorders February 1, 2022 Jianyu Que, Le Shi, Wei Yan et al.

Background Trauma experience increases the risk of suicidal ideation, but little is known about potentially psychological mechanisms underlying this relationship. This study aims to examine the relationship between coronavirus disease 2019 (COVID-19)-related traumatic event (CTE) exposure and suicidal ideation among hospital workers, and identify mediating roles of sleep disturbances in this...

DOI: 10.1016/j.jad.2022.02.033 Full text

The Effectiveness of Repeated Intravenous Ketamine on Subjective and Objective Psychosocial Function in Patients with Treatment-Resistant Depression and Suicidal Ideation.

Journal of Affective Disorders February 1, 2022 Yanling Zhou, Chengyu Wang, Xiaofeng Lan et al.

BACKGROUND Ketamine has rapid and robust antidepressant effects in adults with treatment-resistant depression (TRD), while its effects on functional outcomes have not been sufficiently evaluated. The aim was to evaluate the efficacy of ketamine treatment on both subjective and objective functioning, and to explore whether improvements in depressive symptom and cognition mediated changes in...

DOI: 10.1016/j.jad.2022.02.032

Virtual mindfulness interventions to promote well-being in adults: A mixed-methods systematic review.

Journal of Affective Disorders January 4, 2022 Joy Xu, Helen Jo, Leena Noorbhai et al. 30 citations

BackgroundWith the onset of the COVID-19 pandemic, many have experienced drastic changes in their academic and social lives with ensuing consequences towards their physical and mental well-being. The purpose of this systematic review is to identify virtual mindfulness-based interventions for the well-being of adults aged 19 to 40 years in developed countries and examine the efficacy of these...

DOI: 10.1016/j.jad.2022.01.027 Full text Digital mindfulness. Mental health. Stress reduction. Research review.

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.

Journal of Affective Disorders 2022 L. Mcinnes, Jimmy J Qian, Rishab Gargeya et al. 60 citations

BACKGROUND Outcomes of ketamine intravenous therapy (KIT) for depression in real-world care settings have been minimally evaluated. We set out to quantify treatment response to KIT in a large sample of patients from community-based practices. METHODS We retrospectively analyzed 9016 depression patients who received KIT between 2016 and 2020 at one of 178 community practices across the United...

DOI: 10.1016/j.jad.2021.12.097 Full text

mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.

Journal of Affective Disorders 2022 Lynnette A. Averill, Christopher L. Averill, Ralitza Gueorguieva et al.

Suicide is a public health crisis with limited treatment options. Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI). The parent study for the secondary pilot analyses presented here was a double-blind, cross-over trial that found pretreatment with the mechanistic target of rapamycin complex 1 (mTORC1) prolonged the antidepressant effects of ketamine. Here we...

DOI: 10.1016/j.jad.2022.01.104

Ketamine vs Midazolam: Mood Improvement Reduces Suicidal Ideation in Depression

Journal of Affective Disorders December 1, 2021 Annabella Hochschild, John G Keilp, Sean P Madden et al.

Objective: Studies demonstrate rapid antidepressant and anti-suicidal ideation effects of subanesthetic ketamine. The specific subcomponents of depression that are most closely tied to reduction of suicidal ideation with ketamine treatment are less explored. Methods: Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major...

DOI: 10.1016/j.jad.2021.12.055 Full text

Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.

Journal of Affective Disorders December 1, 2021 Wei Zheng, Lingna Gu, Chen-Hui Sun et al.

OBJECTIVES Anhedonia is a common, persistent, and disabling phenomenon in patients with major depressive disorder (MDD) and bipolar depression (BD). This study was conducted to investigate the comparative effectiveness of repeated ketamine infusions in treating anhedonia in Chinese individuals suffering from MDD and BD. METHODS Ninety-seven individuals suffering from MDD (n=77) or BD (n=20)...

DOI: 10.1016/j.jad.2021.12.105

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.

Journal of Affective Disorders September 17, 2021 Nannan Li, Yi-Ru Hu, Wang-ni Chen et al.

BACKGROUND Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). METHODS Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web...

DOI: 10.1016/j.jad.2021.09.041

The efficacy of mindfulness-based interventions in attention-deficit/hyperactivity disorder beyond core symptoms: A systematic review, meta-analysis, and meta-regression.

Journal of Affective Disorders September 1, 2021 Francesco Oliva, Francesca Malandrone, Giulia Di Girolamo et al.

Mindfulness-Based Interventions (MBIs) have been increasingly proposed as treatment in patients with Attention-Deficit/Hyperactivity Disorder (ADHD), showing promising results on different proposed outcomes, in both children and adults. To systematically review and meta-analyse studies concerning the effects of MBIs on either ADHD and associated features, associated clinical conditions,...

DOI: 10.1016/j.jad.2021.05.068 Full text Adolescents Adults Children Mindfulness-based interventions +1

Multilevel Growth Curve Analyses of Behavioral Activation for Anhedonia (BATA) and Mindfulness-Based Cognitive Therapy Effects on Anhedonia and Resting-State Functional Connectivity: Interim Results of a Randomized Trial

Journal of Affective Disorders May 28, 2021 P. Cernasov, E. Walsh, J. Kinard et al.

Background: The neural mechanisms associated with anhedonia treatment response are poorly understood. Additionally, no study has investigated changes in resting-state functional connectivity (rsFC) accompanying psychosocial treatment for anhedonia. Methods: We evaluated a novel psychotherapy, Behavioral Activation Therapy for Anhedonia (BATA, n=38) relative to Mindfulness-Based Cognitive...

DOI: 10.1016/j.jad.2021.05.054 Full text

Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.

Journal of Affective Disorders March 1, 2021 Roger S McIntyre, Nelson B Rodrigues, Orly Lipsitz et al. 10 citations

BACKGROUND Depression severity and efficacy measurement scales employed for rapid-acting treatments (e.g., ketamine) were initially validated in adults receiving conventional monoamine-based antidepressants. The emergence of rapid-acting antidepressants in psychiatry provides the impetus for outcome measures that have been validated as sensitive to change with rapid-acting treatments. Herein,...

DOI: 10.1016/j.jad.2021.03.053

Not all types of meditation are the same: Mediators of change in mindfulness and compassion meditation interventions.

Journal of Affective Disorders February 2, 2021 Pablo Roca, Carmelo Vázquez, Gustavo Díez et al.

BACKGROUND The general aim of the study was to examine the relative effectiveness and mediators of change in standardized mindfulness and compassion interventions. METHODS A sample of 431 participants enrolled in a Mindfulness-Based Stress Reduction program (MBSR = 277) and a Compassion Cultivation Training (CCT = 154). The assessment before and after the program included a set of outcomes and...

DOI: 10.1016/j.jad.2021.01.070

Acute Effects of Cannabis on Symptoms of Obsessive-Compulsive Disorder.

Journal of Affective Disorders January 15, 2021 Dakota Mauzay, Emily M LaFrance, Carrie Cuttler

Little is known about the the acute effects of cannabis on symptoms of OCD in humans. Therefore, this study sought to: 1) examine whether symptoms of OCD are significantly reduced after inhaling cannabis, 2) examine predictors (gender, dose, cannabis constituents, time) of these symptom changes and 3) explore potential long-term consequences of repeatedly using cannabis to self-medicate for OCD...

DOI: 10.1016/j.jad.2020.09.124 Full text

A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.

Journal of Affective Disorders December 29, 2020 Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz et al.

BACKGROUND Dissociation is a treatment-emergent adverse event commonly associated with IV ketamine, often measured using the 23-item Clinician-Administered Dissociative States Scale (CADSS). The objective of this study was to develop a short form version of the CADSS for easier clinical use. METHODS Retrospective data of 260 patients with treatment-resistant depression (TRD) receiving IV...

DOI: 10.1016/j.jad.2020.12.119

Papers